TrialNeuro-oncology2023

Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.

Scott R Plotkin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.